Clinical trialsOfficial

CBER details rolling submission structure for its Expedited IND Pilot, with most activity before formal IND

🇺🇸 FDA CBER · Wed 04 Nov 2026

FDA's biologics centre says sponsors in the pilot will submit discipline-specific components during pre-IND development, with a QRI vetting each one before the 30-day review begins.

The US Food and Drug Administration's Center for Biologics Evaluation and Research has set out how its Expedited IND Pilot will work. Most of the pilot will take place in the "Pre-IND" phase, the period of nonclinical development before a sponsor files its formal 30-day IND application.

Sponsors will submit discipline-specific components of their pre-IND on a rolling basis through the ESG gateway. Each component is to be framed as a discrete, self-contained package that states the questions on which the sponsor seeks alignment, rather than a partial or fragmentary data drop. Sponsors will propose their own submission timeline, and FDA will not prescribe an order; the sequence will follow the development programme and the advice of the QRI. FDA says it will give pilot participants further guidance on what counts as an IND component and on expected timelines.

Before any component is submitted, the QRI is expected to judge whether it rests on scientifically sound rationale and data. The QRI should give the sponsor clear, actionable feedback, separating issues that must be fixed to avoid a clinical hold from those that would merely strengthen the application. FDA describes the QRI as an accountable scientific partner whose endorsement is a meaningful checkpoint. The source text does not expand the abbreviation QRI.

Sponsors stay responsible for submitting to FDA and for the completeness of the IND package. They may let QRIs act as authorised representatives through Form 1571, but this is not required. Sponsors need not route every remaining component through the rolling process if doing so would delay the final IND; outstanding components can go in with the final submission. That final submission constitutes the complete IND package and starts the 30-day review window. Beforehand, the sponsor and QRI should carry out a final comprehensive evaluation of the package.

FDA will ask sponsors and QRIs for written and verbal feedback from IND-initiating activities until first-in-human trial initiation. This covers the overall process, lessons learned and the QRI's role at each stage, for example whether it only evaluated a finished component or partnered in development. FDA does not intend to enforce strict timelines or requirements for QRI interactions or partnership models, and says it wants industry to find the most productive ways of working together.

What it means for your team

  • Teams considering the pilot should plan for engagement with CBER and data submission earlier than in a conventional IND pathway, since most activity falls in the pre-IND phase.
  • Regulatory operations should prepare to submit self-contained, discipline-specific components via the ESG gateway, each with clear questions for alignment, and to propose a rolling submission timeline.
  • Sponsors keep accountability for IND completeness even where a QRI is involved; Form 1571 authorisation for QRIs is optional.
  • Pilot participants should expect to give structured written and verbal feedback up to first-in-human initiation, and await FDA guidance on component definitions and timelines.

Official source: FDA CBER ↗

Article written by VigiEye from the official source (FDA CBER). AI-assisted; check the source before acting.

More Clinical trials All →